1016 related articles for article (PubMed ID: 9765768)
1. Use of strontium-89 in endocrine-refractory prostate cancer metastatic to bone. Provincial Genitourinary Cancer Disease Site Group.
Brundage MD; Crook JM; Lukka H
Cancer Prev Control; 1998 Apr; 2(2):79-87. PubMed ID: 9765768
[TBL] [Abstract][Full Text] [Related]
2. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial.
Sciuto R; Festa A; Rea S; Pasqualoni R; Bergomi S; Petrilli G; Maini CL
J Nucl Med; 2002 Jan; 43(1):79-86. PubMed ID: 11801708
[TBL] [Abstract][Full Text] [Related]
3. Relative efficacy of 32P and 89Sr in palliation in skeletal metastases.
Nair N
J Nucl Med; 1999 Feb; 40(2):256-61. PubMed ID: 10025832
[TBL] [Abstract][Full Text] [Related]
4. Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Provincial Systemic Treatment Disease Site Group.
Rusthoven J; Bramwell V; Stephenson B
Cancer Prev Control; 1998 Aug; 2(4):179-90. PubMed ID: 10093631
[TBL] [Abstract][Full Text] [Related]
5. Strontium 89 therapy for the palliation of pain due to osseous metastases.
Robinson RG; Preston DF; Schiefelbein M; Baxter KG
JAMA; 1995 Aug; 274(5):420-4. PubMed ID: 7542352
[TBL] [Abstract][Full Text] [Related]
6. The treatment of osseous metastases of hormone-refractory prostate cancer with external beam radiotherapy and Strontium-89.
De Ruysscher D; Spaas P; Specenier P
Acta Urol Belg; 1996 Sep; 64(3):13-9. PubMed ID: 8946776
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant therapy for stage II colon cancer after complete resection. Provincial Gastrointestinal Disease Site Group.
Figueredo A; Germond C; Maroun J; Browman G; Walker-Dilks C; Wong S
Cancer Prev Control; 1997 Dec; 1(5):379-92. PubMed ID: 9765760
[TBL] [Abstract][Full Text] [Related]
8. Bone pain palliation with 85Sr therapy.
Giammarile F; Mognetti T; Blondet C; Desuzinges C; Chauvot P
J Nucl Med; 1999 Apr; 40(4):585-90. PubMed ID: 10210217
[TBL] [Abstract][Full Text] [Related]
9. Epirubicin, alone or in combination chemotherapy, for metastatic breast cancer. Provincial Breast Cancer Disease Site Group and the Provincial Systemic Treatment Disease Site Group.
Findlay BP; Walker-Dilks C
Cancer Prev Control; 1998 Jun; 2(3):140-6. PubMed ID: 10093625
[TBL] [Abstract][Full Text] [Related]
10. Radiopharmaceuticals for the palliation of painful bone metastasis-a systemic review.
Bauman G; Charette M; Reid R; Sathya J
Radiother Oncol; 2005 Jun; 75(3):258-70. PubMed ID: 16299924
[TBL] [Abstract][Full Text] [Related]
11. Painful bone metastases in hormone-refractory prostate cancer: economic costs of strontium-89 and/or external radiotherapy.
Malmberg I; Persson U; Ask A; Tennvall J; Abrahamsson PA
Urology; 1997 Nov; 50(5):747-53. PubMed ID: 9372886
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy in stage IV (metastatic) non-small-cell lung cancer. Provincial Lung Disease Site Group.
Lopez PG; Stewart DJ; Newman TE; Evans WK
Cancer Prev Control; 1997; 1(1):18-27. PubMed ID: 9765723
[TBL] [Abstract][Full Text] [Related]
13. [The efficacy of therapy using 89Sr-strontium chloride in 200 patients with bone metastases of a prostatic cancer].
Haesner M; Buchali K; Pink V; Lips H
Nuklearmedizin; 1992 Mar; 31(2):48-52. PubMed ID: 1373485
[TBL] [Abstract][Full Text] [Related]
14. Strontium-89 as an adjuvant to external beam radiation improves pain relief and delays disease progression in advanced prostate cancer: results of a randomized controlled trial.
Porter AT; McEwan AJ
Semin Oncol; 1993 Jun; 20(3 Suppl 2):38-43. PubMed ID: 7684865
[TBL] [Abstract][Full Text] [Related]
15. Clinical experience with strontium-89 in prostatic and breast cancer patients.
Robinson RG; Preston DF; Baxter KG; Dusing RW; Spicer JA
Semin Oncol; 1993 Jun; 20(3 Suppl 2):44-8. PubMed ID: 8503027
[TBL] [Abstract][Full Text] [Related]
16. Quantitation of biochemical markers of bone resorption following strontium-89-chloride therapy for metastatic prostatic carcinoma.
Papatheofanis FJ
J Nucl Med; 1997 Aug; 38(8):1175-9. PubMed ID: 9255144
[TBL] [Abstract][Full Text] [Related]
17. [Possibilities of systemic radiotherapy with high-purity 89Sr chloride in the treatment of bone metastases].
Fomin DK; Tararukhina OB; Nazarov AA
Vestn Rentgenol Radiol; 2012; (2):29-31. PubMed ID: 22730757
[TBL] [Abstract][Full Text] [Related]
18. Strontium-89 for treatment of painful bone metastasis from prostate cancer.
Altman GB; Lee CA
Oncol Nurs Forum; 1996 Apr; 23(3):523-7. PubMed ID: 8801513
[TBL] [Abstract][Full Text] [Related]
19. Strontium-89 (Metastron) and the bisphosphonate olpadronate reduce the incidence of spinal cord compression in patients with hormone-refractory prostate cancer metastatic to the skeleton.
Soerdjbalie-Maikoe V; Pelger RC; Lycklama à Nijeholt GA; Arndt JW; Zwinderman AH; Papapoulos SE; Hamdy NA
Eur J Nucl Med Mol Imaging; 2002 Apr; 29(4):494-8. PubMed ID: 11914887
[TBL] [Abstract][Full Text] [Related]
20. Surgical management of early stage invasive breast cancer (stage I and II). Provincial Breast Disease Site Group.
Mirsky D; O'Brien SE; McCready DR; Newman TE; Whelan TJ; Levine MN
Cancer Prev Control; 1997; 1(1):10-7. PubMed ID: 9765722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
